Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Why we need novel strategies for diffuse large B-cell lymphoma

Bertrand Coiffier, MD from the Centre Hospitalier Lyon-Sud, Pierre-Bénite, France discusses novel treatment strategies for diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. While R-CHOP chemotherapy is an effective treatment option for the majority of diffuse large B-cell lymphoma patients, there is a significant subset of patients who do not respond as well. Providing examples of recent data, Prof. Coiffier emphasizes the importance of clinical trials in investigating novel, targeted therapies and exploring how these can be used in combination with chemotherapy to achieve superior responses in patients.